Literature DB >> 17557911

Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice.

Ludovic Gomez1, Hélène Thibault, Adbdallah Gharib, Jean-Maurice Dumont, Grégoire Vuagniaux, Pietro Scalfaro, Geneviève Derumeaux, Michel Ovize.   

Abstract

Inhibition of mitochondrial permeability transition pore (mPTP) opening by cyclosporin A or ischemic postconditioning attenuates lethal reperfusion injury. Its impact on major post-myocardial infarction events, including worsening of left ventricular (LV) function and death, remains unknown. We sought to determine whether pharmacological or postconditioning-induced inhibition of mPTP opening might improve functional recovery and survival following myocardial infarction in mice. Anesthetized mice underwent 25 min of ischemia and 24 h (protocol 1) or 30 days (protocol 2) of reperfusion. At reperfusion, they received no intervention (control), postconditioning (3 cycles of 1 min ischemia-1 min reperfusion), or intravenous injection of the mPTP inhibitor Debio-025 (10 mg/kg). At 24 h of reperfusion, mitochondria were isolated from the region at risk for assessment of the Ca(2+) retention capacity (CRC). Infarct size was measured by triphenyltetrazolium chloride staining. At 30 days of reperfusion, mortality and LV contractile function (echocardiography) were evaluated. Postconditioning and Debio-025 significantly improved Ca(2+) retention capacity (132 +/- 13 and 153 +/- 31 vs. 53 +/- 16 nmol Ca(2+)/mg protein in control) and reduced infarct size to 35 +/- 4 and 32 +/- 7% of area at risk vs. 61 +/- 6% in control (P < 0.05). At 30 days, ejection fraction averaged 74 +/- 6 and 77 +/- 6% in postconditioned and Debio-025 groups, respectively, vs. 62 +/- 12% in the control group (P < 0.05). At 30 days, survival was improved from 58% in the control group to 92 and 89% in postconditioned and Debio-025 groups, respectively. Inhibition of mitochondrial permeability transition at reperfusion improves functional recovery and mortality in mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17557911     DOI: 10.1152/ajpheart.01378.2006

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  60 in total

1.  Cyclosporine treatment improves mesenteric perfusion and attenuates necrotizing enterocolitis (NEC)-like intestinal injury in asphyxiated newborn piglets during reoxygenation.

Authors:  Richdeep S Gill; Namdar Manouchehri; Tze-Fun Lee; Woo Jung Cho; Aducio Thiesen; Thomas Churchill; David L Bigam; Po-Yin Cheung
Journal:  Intensive Care Med       Date:  2011-12-06       Impact factor: 17.440

Review 2.  Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis.

Authors:  W Y Lim; C M Messow; C Berry
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  A novel role for mitochondrial sphingosine-1-phosphate produced by sphingosine kinase-2 in PTP-mediated cell survival during cardioprotection.

Authors:  Ludovic Gomez; Melanie Paillard; Megan Price; Qun Chen; Geoffrey Teixeira; Sarah Spiegel; Edward J Lesnefsky
Journal:  Basic Res Cardiol       Date:  2011-10-15       Impact factor: 17.165

4.  Cyclosporin A in left ventricular remodeling after myocardial infarction.

Authors:  Andaleb Kholmukhamedov; Christina Logdon; Jiangting Hu; Richard A McKinney; Francis G Spinale; John J Lemasters; Rupak Mukherjee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-10-25       Impact factor: 4.733

Review 5.  Mechanisms of sudden cardiac death: oxidants and metabolism.

Authors:  Kai-Chien Yang; John W Kyle; Jonathan C Makielski; Samuel C Dudley
Journal:  Circ Res       Date:  2015-06-05       Impact factor: 17.367

Review 6.  Targeting mitochondrial function for the treatment of acute spinal cord injury.

Authors:  Melanie L McEwen; Patrick G Sullivan; Alexander G Rabchevsky; Joe E Springer
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

Review 7.  The molecular composition of the mitochondrial permeability transition pore.

Authors:  Christopher P Baines
Journal:  J Mol Cell Cardiol       Date:  2009-02-20       Impact factor: 5.000

8.  The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1-/- myopathic mice.

Authors:  T Tiepolo; A Angelin; E Palma; P Sabatelli; L Merlini; L Nicolosi; F Finetti; P Braghetta; G Vuagniaux; J-M Dumont; C T Baldari; P Bonaldo; P Bernardi
Journal:  Br J Pharmacol       Date:  2009-06-10       Impact factor: 8.739

Review 9.  Mitochondria as a drug target in ischemic heart disease and cardiomyopathy.

Authors:  Andrew M Walters; George A Porter; Paul S Brookes
Journal:  Circ Res       Date:  2012-10-12       Impact factor: 17.367

Review 10.  Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection.

Authors:  D Morin; R Assaly; S Paradis; A Berdeaux
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.